Rachael L Sherrer1, Zachary A Glaser1, Jennifer B Gordetsky1,2, Jeffrey W Nix1, Kristin K Porter3, Soroush Rais-Bahrami4,5. 1. Department of Urology, University of Alabama at Birmingham, Birmingham, AL, USA. 2. Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA. 3. Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, USA. 4. Department of Urology, University of Alabama at Birmingham, Birmingham, AL, USA. sraisbahrami@uabmc.edu. 5. Department of Radiology, University of Alabama at Birmingham, Birmingham, AL, USA. sraisbahrami@uabmc.edu.
Abstract
BACKGROUND: Multiparametric magnetic resonance imaging (MP-MRI) and MRI/ultrasound (US) fusion-guided biopsy are becoming more widely used techniques for prostate cancer (PCa) diagnosis and management. However, their widespread adoption and use, where available, are limited by cost and added time. These limitations could be minimized if a biparametric MRI (BP-MRI) focusing on T2-weighted and diffusion-weighted imaging is performed. Herein we report the cancer detection rate of BP-MRI compared with full MP-MRI. METHODS: Biopsy-naive and prior negative biopsy patients with clinical suspicion for PCa underwent MP-MRI with an imaging protocol incorporating narrow field-of-view T2-weighted, diffusion-weighted, and DCE pelvic MRI. Then patients underwent MRI/US fusion-guided biopsy of target lesions between November 2013 and October 2017. The pathology results were compared to the positivity of the DCE sequence compared to the BP-MRI findings alone. RESULTS: There were 648 targeted lesions biopsied in 344 patients. We defined biparametric screen filter positivity as both T2-weighted and diffusion-weighted imaging positivity for the same lesion. The majority of target lesions (552/648, 85%) were screen filter positive. For those that were screen filter negative, a minority (14/96, 15%) had DCE-positive findings. Of these, 2/3 (67%) cancer-positive cases were seen on T2-weighted imaging. For those 82 that were screen filter negative and DCE negative, the DCE phase would not have added imaging suspicion. Only 3/82 (3.7%) were cancer positive; 2 with low risk, grade group 1 cancer and 1 with intraductal carcinoma, all identified on targeted T2-weighted MRI positivity. CONCLUSIONS: BP-MRI for the evaluation of PCa and for guiding MRI/US fusion-targeted biopsy has the advantages of reducing cost, time, and contrast exposure of MP-MRI by eliminating the DCE phase. These benefits are realized without forfeiting valuable diagnostic information, as shown by similar cancer detection rates of BP-MRI and MP-MRI in this study, particularly for clinically significant cases of PCa.
BACKGROUND: Multiparametric magnetic resonance imaging (MP-MRI) and MRI/ultrasound (US) fusion-guided biopsy are becoming more widely used techniques for prostate cancer (PCa) diagnosis and management. However, their widespread adoption and use, where available, are limited by cost and added time. These limitations could be minimized if a biparametric MRI (BP-MRI) focusing on T2-weighted and diffusion-weighted imaging is performed. Herein we report the cancer detection rate of BP-MRI compared with full MP-MRI. METHODS: Biopsy-naive and prior negative biopsy patients with clinical suspicion for PCa underwent MP-MRI with an imaging protocol incorporating narrow field-of-view T2-weighted, diffusion-weighted, and DCE pelvic MRI. Then patients underwent MRI/US fusion-guided biopsy of target lesions between November 2013 and October 2017. The pathology results were compared to the positivity of the DCE sequence compared to the BP-MRI findings alone. RESULTS: There were 648 targeted lesions biopsied in 344 patients. We defined biparametric screen filter positivity as both T2-weighted and diffusion-weighted imaging positivity for the same lesion. The majority of target lesions (552/648, 85%) were screen filter positive. For those that were screen filter negative, a minority (14/96, 15%) had DCE-positive findings. Of these, 2/3 (67%) cancer-positive cases were seen on T2-weighted imaging. For those 82 that were screen filter negative and DCE negative, the DCE phase would not have added imaging suspicion. Only 3/82 (3.7%) were cancer positive; 2 with low risk, grade group 1 cancer and 1 with intraductal carcinoma, all identified on targeted T2-weighted MRI positivity. CONCLUSIONS: BP-MRI for the evaluation of PCa and for guiding MRI/US fusion-targeted biopsy has the advantages of reducing cost, time, and contrast exposure of MP-MRI by eliminating the DCE phase. These benefits are realized without forfeiting valuable diagnostic information, as shown by similar cancer detection rates of BP-MRI and MP-MRI in this study, particularly for clinically significant cases of PCa.
Authors: Jeffrey C Weinreb; Jelle O Barentsz; Peter L Choyke; Francois Cornud; Masoom A Haider; Katarzyna J Macura; Daniel Margolis; Mitchell D Schnall; Faina Shtern; Clare M Tempany; Harriet C Thoeny; Sadna Verma Journal: Eur Urol Date: 2015-10-01 Impact factor: 20.096
Authors: Ivo G Schoots; Monique J Roobol; Daan Nieboer; Chris H Bangma; Ewout W Steyerberg; M G Myriam Hunink Journal: Eur Urol Date: 2014-12-03 Impact factor: 20.096
Authors: Vidhush K Yarlagadda; Win Shun Lai; Jennifer B Gordetsky; Kristin K Porter; Jeffrey W Nix; John V Thomas; Soroush Rais-Bahrami Journal: Diagn Interv Radiol Date: 2018 May-Jun Impact factor: 2.630
Authors: Ashkan A Malayeri; Kristina M Brooks; L Henry Bryant; Robert Evers; Parag Kumar; Daniel S Reich; David A Bluemke Journal: J Am Coll Radiol Date: 2016-01-23 Impact factor: 5.532
Authors: Hashim U Ahmed; Ahmed El-Shater Bosaily; Louise C Brown; Rhian Gabe; Richard Kaplan; Mahesh K Parmar; Yolanda Collaco-Moraes; Katie Ward; Richard G Hindley; Alex Freeman; Alex P Kirkham; Robert Oldroyd; Chris Parker; Mark Emberton Journal: Lancet Date: 2017-01-20 Impact factor: 79.321
Authors: Michele Fascelli; Soroush Rais-Bahrami; Sandeep Sankineni; Anna M Brown; Arvin K George; Richard Ho; Thomas Frye; Amichai Kilchevsky; Raju Chelluri; Steven Abboud; M Minhaj Siddiqui; Maria J Merino; Bradford J Wood; Peter L Choyke; Peter A Pinto; Baris Turkbey Journal: Urology Date: 2015-12-08 Impact factor: 2.633
Authors: Armando Stabile; Francesco Giganti; Veeru Kasivisvanathan; Gianluca Giannarini; Caroline M Moore; Anwar R Padhani; Valeria Panebianco; Andrew B Rosenkrantz; Georg Salomon; Baris Turkbey; Geert Villeirs; Jelle O Barentsz Journal: Eur Urol Oncol Date: 2020-03-17
Authors: Tae Il Noh; Chang Wan Hyun; Ha Eun Kang; Hyun Jung Jin; Jong Hyun Tae; Ji Sung Shim; Sung Gu Kang; Deuk Jae Sung; Jun Cheon; Jeong Gu Lee; Seok Ho Kang Journal: Cancer Res Treat Date: 2020-12-31 Impact factor: 4.679